There is an increasing demand for higher productivity and increased efficiency in bioprocess manufacturing. There have been improvements made in the efficiency of that process in the upstream area, such as more efficient cell culture systems. That is starting to put pressure on the downstream processing, as this is required to accommodate higher volumes.
The highest costs in a production process arise from the downstream processing. Therefore, understanding the biophysical properties of the viral vectors helps to choose the optimal parameters and conditions and subsequently, can be beneficial to decide which unit operations or process steps can be reduced to minimize product losses during the process.
In this Q&A, Marc Hummersone, Senior Director of R&D at Astrea Bioseparations, discusses the evolving challenges of downstream processing for advanced therapies, and what the future might hold. He also describes the company’s Discover. Develop. Deliver. approach to customer alignment, along with selection considerations of off-the-shelf and customized downstream solutions.
As seen in Biopharminternational.com